FDA Agrees with Galmed s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(1)
Circulating cell-free mRNA in blood reflective of NAFLD/NASH liver pathology
PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the company s Next-Generation cell-free mRNA Liquid Biopsy Technology Platform. The study titled Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization was published in the
American Journal of Physiology -
Gastrointestinal and Liver Physiology, a journal of the American Physiological Society. The first author is Naga Chalasani, M.D., Professor of Gastroenterology and Hepatology and Interim Chair in the Department of Medicine at Indiana University in the USA. Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and
ResearchAndMarkets.com’s offering.
Sales for the NASH market to grow from $144.4M in 2019 to $27.2B in 2029 at a Compound Annual Growth Rate (CAGR) of 68.8% across the 7MM.
At the end of 2029, the US will contribute around 94.3% of global sales, while the 5EU and Japan will account for around 4.5% and 1.2% of sales, respectively.
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage. Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem. However, symptoms including fatigue, weight loss, and weakness emerge once the disease has progressed to a more advanced stage, like cirrhosis. NASH is suspected if elevated liver enzymes are detected during routine blood panels, but it is only